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ABSTRACT 
Objective:  To determine the true prevalence of HIV dual infections in a previously 
characterised HIV seropositive patient group due to inconsistencies between different 
diagnostic methods.
Design: A cross-sectional study of an HIV seropositive group with different diagnostic 
methods.
Setting: Three hospitals in the Northern, Ashanti and Greater Accra Regions of Ghana. 
Subjects: One hundred and forty five HIV infected patients/individuals sampled from 
June to September 2002.
Main outcome measures:  Using serological and molecular methods, the seropositive 
status of HIV-infected patients, previously determined by a preliminary screening 
process, was confirmed and discrepancies noted. The data was used to propose a more 
accurate laboratory diagnosis of HIV dual infections involving HIV-1 and HIV-2. 
Results:  HIV-1 infections were mostly accurately detected, but difficulties were 
encountered in diagnosing HIV-2 infections. To achieve a positive detection on 
confirmatory immunoblots, antibody concentration in some samples tested was 
enhanced by using larger volumes. In other cases, diagnosis of HIV infections by 
PCR, especially HIV-2, was possible only after increasing the DNA template or MgCl2 
concentrations. Such samples would otherwise have been inaccurately scored for HIV 
infections. 
Conclusion:  Based on the results of this study, we propose that the accurate diagnosis 
of HIV dual infections, especially HIV-2 component, must use an algorithm that 
involves PCR. Our results however underscore conclusions of a previous study that 
most dually seroreactive samples are predominantly HIV-1 infections with cross-
reactivity to HIV-2 antigens.
INTRODUCTION 
The AIDS epidemic in Ghana was initially due to 
HIV Type 2 (HIV-2) (1). HIV Type 1 (HIV-1), was 
introduced into Ghana in the mid 90s predominates 
and now accounts for over 90% of all HIV/AIDS cases 
where HIV-2 was originally predominant (2, 3). About 
2% of the infections are currently due to HIV-2 alone 
while 2-3% is categorised as dual infections, based 
on serological data.
 HIV-1 and HIV-2 infections differ markedly 
in their prognosis and necessarily require different 
therapeutic approaches. For example HIV-1 subtype 
0 and HIV-2 strains are naturally resistant to non-
nucleoside reverse transcriptase inhibitor (NNRTI) 
group of antiretroviral drugs (ARVs) (4). Also, some 
HIV-1 group M viruses including subtype G strains 
and CRF02_AG recombinants are differentially 
susceptible to protease inhibitors (PIs) (5, 6). 
Estimating the true prevalence of HIV-1 and HIV-2 
infections, as well as co-infections with both types 
is therefore necessary to successfully control the 
epidemic. HIV-2 is much less studied relative to HIV-1 
and further work involving HIV-2 will be enhanced 
by the availability of molecular data on circulating 
HIV-2 species, as well as critical information on 
phenotypic properties of the virus. These will 
facilitate intervention efforts like development of 
a safe, effective and affordable vaccine to manage 
the pandemic. Achieving these objectives depends 
significantly on the accurate laboratory diagnosis of 
H IV-2 and, by extension, dual H IV-1/2 infections. 
 In Ghana, previous studies demonstrated a 
misdiagnosis of HIV dual infections (7, 8). This study 
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shows that the laboratory diagnosis of HIV-2 infection 
remains problematic. It is therefore necessary to 
optimise conditions for its detection in areas where 
dual infections are prevalent. We determined the 
proportion of dual infections among Ghanaian HIV 
seroreactive patients  and indicated the possible 
sources of error that must receive attention in the 
accurate  diagnosis of dual HIV infections.
MATERIALS AND METHODS 
Patients and sample collection: Venous blood was 
aseptically collected from 145 HIV-infected 
individuals reporting to three hospitals in the 
Northern, Ashanti and Greater Accra Regions of 
Ghana from June to September 2002. These comprised 
asymptomatic HIV infected individuals and AIDS 
patients. Patient selection and sampling were done 
only after obtaining informed consent from the 
subjects. Eight mls of blood were then collected into 
vacutainer tubes with EDTA anti- coagulant. The 
samples were transported in cold boxes from the 
hospitals to Noguchi Memorial Institute for Medical 
Research (NMIMR) within 24hrs of collection. At 
NMIMR, the plasma was  separated and stored at 
-20ºC. Peripheral blood mononuclear cells (PBMCs) 
were isolated from the rest of the blood as described 
(9) and stored at -70ºC until used. 
Serological assays: The serological status of the patients 
for HIV infection was re-checked by two rapid assays, 
namely Determine (Dainabot Co. Ltd, Japan) and 
HIVSPOT (Genelabs Diagnostics, Singapore). A 
Serodia particle agglutination (PA) kit (Fujirebio Inc., 
Japan,) was used for the  initial HIV typing. Dually 
reactive samples on PA were further analysed to 
confirm their dual infection status. Peptilav HIV-
1/2 assay (Diagnostic Pasteur, France), and Innolia 
HIV-1/2 assay (Innogenetics, Belgium) were used 
for the diagnosis of either HIV-1 or HIV-2. Peptilav 
employed synthetic peptides to the mono-epitope of 
the transmembrane glycoproteins of HIV-1 and HIV-
2 (gp 41 and gp 36 respectively) for differentiation. 
Dual positive samples were simultaneously reactive 
to both antigens (10). Innolia had several HIV 
antigens spanning the viral envelope and the core. 
The criteria for positivity by Innolia were the presence 
of two envelope glycoprotein bands or one envelope 
glycoprotein and a core protein band according  to 
the manufacturer’s directives. 
Polymerase chain reaction (PCR): Genomic DNA of HIV 
provirus was extracted from PBMCs of PA dually 
reactive samples in  lysis buffer composed of 10 mM 
Tris-HCL, pH 9.0, 50 mM KCI, 1.5 mM MgCl2 and 
0.5% Tween  20. Lysis was performed by incubating 
the specimens for three hours in a water bath at 55ºC. 
Iminodiacetic acid (50% Chelex-100) was added to a 
final concentration of 5%. The mixture was heated at 
95°C for eight minutes and mixed for eight seconds. 
DNA associated proteins were digested with 0.6 
mg/ml of proteinase-K (Sigma, USA). Samples  were 
then centrifuged, the DNA-containing supernatant 
carefully taken into fresh tubes and stored at -30°C 
until used. Each amplification was preceded by PCR 
for a cellular gene, ß2- microglobulin, to assess the 
quality of DNA extracted.  
 In the quality assessment reaction, 2.5 µL of DNA 
template was amplified in a single round assay with 
1.25 U of AmpliTaq Gold® (Roche, Molecular Systems 
Inc. NJ, USA) and 10x PCR buffer with 25 mM MgCI2 , 
2 mM of each deoxy-nucleotidetriphosphates (dNTPs) 
and 10 µM each of forward and reverse primers in a 
final volume of 25 µL. Cycle conditions were 10 mins 
at 95ºC followed by 35 cycles of 30 secs at 94ºC, 30 
secs at 45ºC, and 1 min at 72ºC in a Gene Amp PCR 
Systems 2400 thermal cycler (Perkin-Elmer, Norwalk, 
CT). A final extension step at 72ºC was performed for 
7 mins. A full-length PBMC-derived clone, positive 
for HIV-1 or HIV-2, and a plasmid containing a 
known HIV unreactive sample respectively served as 
positive and negative controls. To guarantee primer 
specificity, all primer pairs (Table 1) were pre-tested 
on the positive HIV-1 and HIV-2 as well as negative 
controls in a one-round PCR assay using cycle 
conditions stated earlier. Adequate measures were 
taken to avoid cross-contamination by preparing PCR 
mixtures in separate dedicated safety hoods while 
pre- and post-PCR manipulations were performed 
in different rooms. Furthermore, aerosol-resistant 
pipette tips were used throughout the procedure. 
 A nested PCR was performed as previously 
described (11). The first round conditions were the 
same as for the one-round DNA quality assessment 
PCR referred to above. In the second round reaction, 
1 µL of the first round product was amplified in a fresh 
25 µL reaction mixture under the following conditions: 
10 minutes at 95 °C followed by 35 cycles of 30 secs 
at 94ºC, 30 secs at 55ºC, and 1 min at 72°C plus an 
extension of 7 mins. Five µL of amplification products 
were eletrophoresed in 2% agarose gel (Sigma, USA) 
prepared in Tris-borate-EDTA (TBE) buffer alongside 
a molecular weight marker and viewed under UV 
light after ethidium bromide (10 mg/ml) staining. A 
positive reaction on a test sample with one or both 
HIV-1 (pol or env-located) primer sets was interpreted 
as HIV-1 PCR positive infection. Similarly a positive 
result with one or both HIV-2 (L TR-located) primer 
sets on a test sample was indicative of a PCR-reactive 
HIV-2 sample. 
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Table 1
Nucleotide sequence of PCR primers 
Primer Name  Nucleotide sequence (5’ - 3’) Expected    
Description   product size 
    (bp)   
ß2- GH 20 GAAGAGCCAAGGACAGGTAC   
microglobulin GH 21 GGAAAATAGACCAATAGGCAG 408 
 HPOL 4325 CCCTACAATCCCCAAAGTCAAGG (4653-4676) *   
HIV-1** HPOL 4538 TACTGCCCCTTCACCTTTCCA (4956-4977) 154 
 (Pol) HPOL 4327 TAAGACAGCAGTACAAATGGCAG (4745-4768)   
   HPOL 4481 GCTGTCCCTGTAATAAACCC (4900-4920)   
  
 OA3 TGTACACATGGAATTAGGCCAGTAG (6963-6987)   
HIV OD3 AAA TTCCCCTCCACAATTAAAACTG (7346-7371) 348 
(Env) SB TCAACTCAACTGCTGTTAAAT (6990-7011)   
   SC AATTTCTGGGTCCCCTCCTGAGG (7315-7338)   
HIV-2 LTRA CTGAGACTGCAGGGACTTTCCAGAAGGG (9379-9406)   
(3’-5’ LTR) LTRB AAGCAAGAAGGGTCCTAACAGACCAGGGT (241-270)   
   LTRC GGGA T ACTGCAGCAACAGCAACAGCTGTTG (7782-7811)  506 
 LTRD CCAGGCGGCGACTAGGAGAGATGGGAGCAC (184-213)   
HIV-2 ** H2L100 GCTGGCAGATTGAGCCCTG (18-35)   
 (5’ LTR) H2L 101 AAGGGTCCTAACAGACCAGGG (241-263)   
   H2L200 CAGCACTAGCAGGTAGAGCCTGGG (49-71) 150 
   H2L201 GGCGGCGACTAGGAGAGATGG (191-210)
   
* Figures in parenthesis indicate primer locations on HXB2 (HIV-1) or HIV-2 ROD. 
**Primers were previously published in Ref 11 
Statistical analysis: PCR assay was considered as 
the reference standard in this study. Data thereby 
generated were compared with the two serological 
confirmatory assays, Peptilav and Innolia. Sensitivity 
(ability to correctly diagnose true positive infections) 
and specificity (ability to correctly diagnose true 
negative infections) of the assays were analysed in 
order to assess the performance of the three assays on 
the same sample set in the accurate diagnosis of HIV 
infections. Sensitivity was determined according to 
the formula {TP/(TP+FN)} x 100 where TP was true 
positive and FN was false negative. Specificity was 
determined by {TN/(TN+FP)} x 100, where TN was 
true negative and FP was false positive (12). 
RESULTS 
Diagnosis of HIV-1 infection: One hundred and forty 
five HIV seropositive samples were analysed further 
by rapid screening with Determine and HIVSPOT and 
typed by Serodia PA, during which PA scored 106/145 
(73%) seropositive HIV-1 infections. None was reactive 
for HIV-2 alone, while 39/145 (27%) were dually 
seropositive (Table 2). Subsequent analysis of 37 of the 
39 PA dually reactive samples by Innolia, Peptilav  and 
PCR are detailed in Table 3 and summarised in Table 
4. Peptilav and Innolia respectively diagnosed 29 and 
32 samples as HIV-1 only infections. The two assays 
identified seven and five additional HIV-1 infections 
respectively, which occurred simultaneously with HIV-2 
as dual infections. In total, therefore, Peptilav scored 
36/37 (97%) HIV-1 infections, while lnnolia diagnosed 
37/37 (100%) as HIV-1 infections (Table 3). PCR, on 
the other hand diagnosed 26 HIV-1 only infections and 
11 additional ones occurring simultaneously with HIV-2 
as dual  infections. Overall, PCR scored 37/37 (100%) 
HIV-1 infections.
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Table 2
Summary of subsequent tests performed on 145 previously characterised HIV seropositive patient samples       
            Result of Assay       
   HIV HIV     HIV 1/2 dual
Name of assay Type of assay Positive Negative HIV-1 HIV-2 infection 
HIVSPOT HIV screening 145       
  (100%) 0 NA NA NA 
DETERMINE HIV screening 145       
   (100%) 0 NA NA NA 
SERODIA PA HIV typing 145  105  39 
  (100%) 0 (73%) 0 (27%) 
NA = not applicable
Table 3
Diagnosis of HIV infection among 37 PA-dually reactive samples by immunoblot and PCR assays       
Sample No. Sample ID No.          Immunoblots   PCR
  Peptilav Innolia 
1 E2 Dual HIV-1 HIV-1
2 E3 Dual HIV-1 HIV-1
3 E4 Dual HIV-1 Dual
4 E5 HIV-1 HIV-1 HIV-1
5 E6 HIV-1 HIV-1 Dual**
6 E7 HIV-1 HIV-1 HIV-1
7 E8 HIV-1 HIV-1 HIV-1
8 E9 HIV-1 HIV-1 HIV-1
9 E13 HIV-1 HIV-1 HIV-1
10 E14 HIV-1 HIV-1 Dual
11 E15 HIV-1 HIV-1 HIV-1
12 E16 HIV-1 HIV-1 Dual**
13 E17 HIV-1 Dual HIV-1
14 E18 HIV-1 HIV-1 HIV-1
15 E19 HIV-1 HIV-1 Dual
16 E20 HIV-1 HIV-1 Dual**
17 E21 HIV-1 HIV-1 HIV-1
18 E22 HIV-1 HIV-1 HIV-1
19 E23 Dual Dual Dual 
20 E24 Dual HIV-1 Dual 
21 E25 HIV-1 HIV-1 Dual 
22 E26 HIV-1 HIV-1 HIV-1
23 E27 HIV-1 HIV-1 HIV-1
24 E28 HIV-1 HIV-1 HIV-1
25 E29 HIV-1 HIV-1 HIV-1
26 E30 HIV-1 HIV-1 HIV-1
27 E31 HIV-1 HIV-1 HIV-1 
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Continuation of Table 3
28 E32 HIV-1 HIV-1 HIV-1
29 E33 HIV-1 HIV-1 HIV-1
30 E34 HIV-1 HIV-1 HIV-1
31 E35 Dual HIV-1 HIV-1
32 E36 HIV-1 HIV-1 HIV-1
33 E37 HIV-1 HIV-1 HIV-1
34 E38 HIV-1 HIV-1 HIV-1
35 E41 HIV-2 Dual Dual** 
36 E42 HIV-1 Dual HIV-1 
37 E43  Dual  Dual Dual 
*    HIV-2 detected only at increased MgCl2 concentration
**  HIV-2 detected after increasing template concentration 
Table 4
Sensitivity and specificity of PCR, Peptilav and Innolia assays in diagnosis of HIV-1 and HIV-2 infections 
among 37 PA dual positive samples 
Assay Infection Positive
 type samples  TP* TN FP FN Sensitivity Specificity
  No.  (%)       (%) (%)
 
Peptilav HIV-1 36   97 36 0 0 1 97 NA
 HIV-2 8    22 8 29 3 3 73 91
Innolia HIV-1 37  100 37 0 0 0 100 NA
 HIV-2 5        14 5 32 6 6 45 84
PCR HIV-1 37    100 37 0 0 0 100 NA*
 HIV-2 11      30 11 26 0 0 100 100 
* TP = True positive,  TN = True negative,  FP = False positive,  FN =False negative,  NA=not applicable 
Diagnosis of HIV-2 infection: Peptilav alone identified 
one case (E 41) of HIV-2 only infection. Seven 
additional HIV-2 infections were identified as dual 
infections with HIV-1. Thus Peptilav scored 8/37 HIV-
2 cases.  Innolia and PCR respectively scored 5/37 
and 11/37 cases. In total, HIV-2 infections diagnosed 
were 11 (30%) by PCR, nine (22%) by Peptilav and 
five (14%) by Innolia. 
Diagnosis of dual infection: Dual HIV-1/2 infections 
diagnosed by the three assays were similar to HIV-2 
infections.  Innolia identified 5/37 (14%) serologically 
dual reactive samples while Peptilav identified 8/37 
(22%). PCR scored the highest number of dually 
reactive samples of 11/37 (30%). 
Sensitivity and specificity of assays: PCR and Innolia 
both had 100% sensitivity in the diagnosis of HIV-
1 infections, while Peptilav had 97% sensitivity. 
Peptilav scored a single false negative case for HIV-1 
infection. Specificity could not be determined for the 
assays, however, because our test samples did not 
include HIV-1 negative cases. Sensitivity for HIV-2 
diagnosis was remarkably varied among the three 
assays. PCR had 100%, 73% for Peptilav and 45% 
for Innolia. Peptilav diagnosed 3/11 false negative 
samples, while Innolia diagnosed 6/11 false negative 
HIV-2 infections. Specificity of the three assays in the 
diagnosis of HIV-2 infections was 100% for PCR, 91% 
for Peptilav and 84% for lnnolia (Table 4). Peptilav 
and Innolia respectively diagnosed three and six false 
positive cases of HIV-2 infections. 
DISCUSSION 
A reliable estimation of the frequency of dual 
infections has difficulties due to discrepancies  that are 
peculiar to the different serological tests and genomic 
amplification methods employed (13). Peptilav and 
Innolia differed in the number of antigens used in 
their manufacture. Innolia possessed five HIV-1 
antigens, namely the envelope transmembrane (TM) 
glycoprotein (gp) 41, an additional env antigen (gp120), 
as well as core antigens p31 (integrase), p17 (gag 
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protein) and p24 (capsid). Peptilav, on the other hand, 
had only one HIV-1 antigen, namely gp41. However, 
only 3% disparity was observed between the two 
assays in the diagnosis of HIV-1 infections. Innolia, not 
surprisingly, detected 100% HIV-1 reactive samples, 
while the number diagnosed by Peptilav, (97%), was not 
significantly different from lnnolia. There was however 
a discrepancy of 8% between Innolia and Peptilav in 
the diagnosis of HIV-2 and 28% in identification of 
dual HIV infections, exhibiting considerable diversity 
between the two assays. In both cases Peptilav correctly 
diagnosed more of the infections than Innolia. This 
observation was surprising since Innolia had extra 
antigens to both HIV-1 and HIV-2. For HIV-2 diagnosis, 
Innolia had gp 105 in addition to gp 36 and a strong 
reactivity to either one or both, along with a core antigen 
was interpreted as a positive result according to the 
manufacturer. Effectively, plasma HIV-2 antibodies 
in our samples missed out on both HIV-2 antigens in 
Innolia more frequently than they did on the single 
HIV-2 epitope in Peptilav during HIV-2 diagnosis. 
 The level of HIV-2 diagnosis achieved 
genomically on this sample set (30%) was considered 
to best reflect the true HIV-2 prevalence in Ghana. 
This is because diagnosis of HIV infections by PCR 
relies on the detection of proviral sequences within 
the host cell genome, which is a marker for viral 
presence. A positive PCR result thus represented a 
definite episode of HIV infection, hence the decision to 
consider this assay as the ‘gold standard’.  However, 
even by PCR, the template amount had to be doubled 
to improve sensitivity in, at least, three cases before 
achieving a positive HIV-2 diagnosis (samples E6 and 
E16) and a positive HIV-1 diagnosis for E41. With E20 
also, HIV-2 provirus was detected only after MgCl2 
concentration had been doubled. These underscore 
the results of previous reports that it is possible to 
improve the detection of HIV-2 provirus in samples 
with a dual serological profile (14). 
 Discordant data between serological and 
genomic-based assays have been reported in other 
West Africa countries (14, 15). For example specimens 
initially diagnosed as dually seroreactive on 
immunoblots were subsequently shown to have only 
HIV-1 proviral sequences, a situation reminiscent of 
the cross reactivity between HIV-1 and HIV-2 antigens.
Again Leonard et al. (16) reported the detection 
of HIV-2 provirus in samples confirmed as HIV-1 
only on immunoblots. In our study, both HIV-1 and 
HIV-2 proviral sequences were detected in six samples 
(E6, E14, E16, E19, E20 and E24) which were earlier 
confirmed as HIV-1 only on immunoblots. 
 The disparity in the detection of H IV infections 
among our samples could also reflect the genetic 
diversity of circulating HIV molecular forms in Ghana 
and, possibly, the West African subregion. At the time 
of this study, the epidemic in Ghana was due to the 
co-circulation of HIV-1 subtypes A, D and G (7, 17), 
HIV-2 subtypes A and B (18) and possibly CRF02_AG 
recombinant strains, which currently predominate 
in Ghana (8). New recombinants such as CRF06_cpx 
now prevail in West Africa (19). Furthermore HIV-1 
subtypes A, G, J and CRF01_AE have also variously 
recombined to create CRF11_cpx in Cameroon and 
the Central Africa Republic (20). These developments 
underscore the extent of genetic diversity and the 
potential for the emergence of new HIV variants in 
West and Central Africa. The interaction between these 
variants and the immunological characteristics of the 
resulting phenotypes are not altogether predictable. 
This study was carried out with 3rd generation kits 
composed of antigenic peptides designed to encompass 
all documented major HIV strains at that time. Indeed, 
all three assays were inherently capable of achieving 
the same diagnosis for some of our specimens. For 
example, apart from the several instances of a uniform 
diagnosis of HIV-1 infection, samples E23 and E43 
were both scored as dual infections by all three assays 
evaluated. The inability of these assays, therefore, to 
correctly diagnose all the test samples at all times 
could be related, most probably, to unique circulating 
HIV recombinants. Since the assays virtually detected 
all HIV-1 infections, the difficulty with the accurate 
diagnosis of HIV dual infections was largely due to 
inaccuracies in the serological detection of HIV-2. This 
was exemplified with Peptilav, Innolia and, to an even 
larger extent, Serodia PA. 
In conclusion, the reliable diagnosis of dual infections 
is characterised by some difficulties in areas where 
HIV-1 and HIV-2 co circulate. It appears that many 
assays will correctly identify HIV-1 infections. 
However, for the accurate serological diagnosis of 
HIV-2 infections, enhancement of plasma antibody 
levels was necessary. We also showed that a positive 
PCR diagnosis for HIV-2 required modification of 
template or MgCI2 concentrations. The critical issue 
raised in this study is that using anyone assay on the 
test samples resulted in different outcomes. 
 Walther-Jallow et al (13) reported that a 
combination of PCR and different serological assays 
achieved up to 85% success in the detection of dual 
HIV infections. In our view, samples must be subjected 
to an immunoblot assay such as Peptilav, with at least 
two increasing amounts of the test samples. Because 
serology alone could overestimate the prevalence of 
dual infections, serologically reactive samples must 
be re-evaluated by PCR as prescribed earlier. The 
accurate diagnosis of dual infections must involve 
PCR. This proposed algorithm implies that accurate 
diagnosis of HIV-1/2 dual infections will necessarily 
require highly trained personnel and a well-resourced 
laboratory. This will also be expensive but unavoidable 
because with the increasing availability of ARVs to 
HIV/AIDS patients in West Africa and elsewhere, it 
will be critical to correctly diagnose HIV infections 
in these populations to guarantee optimal treatment 
of AIDS disease. 
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